AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

Jul 21, 2017

AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis

NORTH CHICAGO, Ill., July 21, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for HUMIRA® (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients from two years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Jul 10, 2017

AbbVie to Host Second-Quarter 2017 Earnings Conference Call

NORTH CHICAGO, Ill., July 10, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2017 financial results on Friday, July 28, 2017, before the market opens.

Jun 26, 2017

6,000 Employees in More Than 50 Countries Join Together as #AbbVieGivesBack

NORTH CHICAGO, Ill., June 26, 2017 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, and its key partners celebrate the launch of the fourth annual "Week of Possibilities," with more than 6,000 employees expected to volunteer  26,000+ hours in the communities where they live and work. AbbVie volunteers will join forces with nonprofit partners like Heart of America Foundation and Points of Light, engaging in hands-on projects that largely focus on improving educational opportunities for children in underserved communities.

Jun 23, 2017

AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

NORTH CHICAGO, Ill., June 23, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending marketing authorization of MAVIRET™ (glecaprevir/pibrentasvir), an investigational, pan-genotypic treatment for adults with chronic hepatitis C virus (HCV) infection. If approved, MAVIRET will be a once-daily, ribavirin-free, 8-week option for patients without cirrhosis and who are new to treatment across all genotypes (GT1-6), who comprise the majority of people living with HCV.1 The European Commission will now review the CHMP opinion and a final decision is expected in Q3 2017.

Jun 22, 2017

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., June 22, 2017 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.64 per share. 

Jun 13, 2017

AbbVie Presents Real-World Data Evaluating the Relationship between Participation in a Patient Support Program and Outcomes in Patients with Moderate to Severe Rheumatoid Arthritis

- New data of rheumatoid arthritis patients who participated in a HUMIRA (adalimumab) patient support program in select countries showed an association between the use of a patient support program and improvements in functional outcomes

Jun 13, 2017

AbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., June 13, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, announced today that they have entered a collaboration for the development of oral immunoproteasome inhibitors.  The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology. 

Jun 12, 2017

AbbVie Announces New Data Evaluating Venetoclax in a Variety of Hematologic Malignancies at the 22nd European Hematology Association Congress

- Results from pivotal VENCLYXTO (venetoclax) trial in relapsed/refractory chronic lymphocytic leukemia (CLL) patients with 17p deletion to be presented

Jun 07, 2017

AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Phase 3 Study in Rheumatoid Arthritis

NORTH CHICAGO, Ill., June 7, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-NEXT clinical trial evaluating upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis (RA) who did not adequately respond to treatment with conventional synthetic DMARDs (csDMARDs).1 Results showed that after 12 weeks of treatment, both doses of upadacitinib (15 mg and 30 mg) met the study's primary endpoints of ACR20 and low disease activity.1 Key secondary endpoints were also achieved and included ACR50, ACR70 and clinical remission.1 Full results will be presented at an upcoming medical meeting and published in a peer-reviewed publication. Upadacitinib is an investigational oral agent and is not approved by regulatory authorities.